Resistance of hospital urinaryinfection pathogens by the data of multicenter microbiologicalstudies UTIAP-I and UTIAP-II
- Authors: Rafalsky VV1, Strachunsky LS1, Krechikova OI1, Eidelstein IA1, Akhmetova LI1, Babkin PA1, Gugutsidze EN1, IIyina VN1, Kogan MI1, Kopylov VV1, Malev IV1, Petrov SВ1, Rafalskaya LV1, Furletova NM1
-
Affiliations:
- Issue: No 2 (2004)
- Pages: 13-17
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/275009
- ID: 275009
Cite item
Full Text
Abstract
isolated from adult outpatients with uncomplicated urinary infection
(UI) in different regions of Russia.
Material and methods. A multicenter prospective epidemiological
study included adult patients with uncomplicated infections of the upper
or lower urinary tracts. MPK of antibiotics was established by dilution
in agar according to NCCLS recommendations, 2000-2002.
Results. Among UI causative agents, E.coli was most frequent
(85.9%). K. Pneumoniae, Proteus spp., Staphylococcus spp., P. Aeruginosa,
Enterococcus spp.occurred much less frequently (6, 1.8, 1.6,1.2,
and 1.0%, respectively). E. Coli UI was highly resistent to ampicilline (37.1%),
cotrimoxasol (21%),maximal resistance being in St-Petersburg
(51.9 and 31.5%, respectively). Such oral antibiotics as
norfloxacin and ciprofloxacin, cefuroxim, amoxicillin/clavulanat, nitrofurantoin
were maximally active against E. Coli (4.3, 2.4, 2.6 and
1.2%, respectively).
Conclusion. High resistance of E.coli, which is the chief causative
agent of uncomplicated UI, to ampicillin, cotrimoxasol was detected.
Fluoroquinolones, amoxicillin/clavulanat, nitrofurantoin, cefuroxim
have high microbiological activity. On the basis of the pharmacokinetic,
safety and other evidence it is concluded that drugs of choice
for therapy of uncomplicated UI in Russia are oral fluoroquinolones
About the authors
V V Rafalsky
L S Strachunsky
O I Krechikova
I A Eidelstein
L I Akhmetova
P A Babkin
E N Gugutsidze
V N IIyina
M I Kogan
V V Kopylov
I V Malev
S В Petrov
L V Rafalskaya
N M Furletova
References
- Лоран О. Б. Эпидемиологические аспекты инфекций мочевыводящих путей. В кн.: Материалы Международного симпозиума "Инфекции мочевыводящих путей у амбулаторных больных". М.; 1999. 5-8.
- Hooton Т. М., Stamm W. E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. N. Am. 1997; 11 (3): 551-581.
- Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J. Antimicrob. Chemother. 2003; 51 (1): 69-76.
- Karlowsky J. A., Kelly L. J., Thornsberry C. et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 2002; 46 (8): 2540-2545.
- Raz R., Chazan В., Kennes Y. et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geograhical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 2002; 34 (9): 1165-1169.
- Warren J. W., Abrutyn E., Rebel J. R. et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. 1999; 29 (4): 745-758.
- NCCLS methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. In: Approved standard. 6-th ed. West Valley Road; 2002; Vol. 20: 1-45.
- Comite de l'antibiogramme de la societe francaise de microbiologie (CA-SFM): report 2003. Zone sizes and MIC breakpoints for non-fastidious organisms (<http://www.sfm.asso.fr/>).
- Mazzulli Т., Sarabia A., Marshall W. et al. Susceptibility of community urinary tract isolates to commonly used oral antimicrobial agents. In: 42-nd Interdisciplinary congress of antimicrobial agents and chemotherapy: Abstracts. San Diego, California; 2002. abstr. C2-318.
- Козлов С. Н., Рачина С. А., Домникова Н. П. и др. Фармакоэпидемиологический анализ лечения внебольничной пневмонии в амбулаторных условиях. Клин, микробиол. и антимикроб, химиотер. 2000; 3: 74-81.
- Андреева И. В., Рачина С. А., Петроченкова Н. А. и др. Самостоятельное применение антимикробных препаратов населением: результаты многоцентрового исследования. Клин, фармакол. и тер. 2002; 3: 15-26.
- Bergogne-Berezin E., Berthelot G., Muller-Serieys С. Present status of nitroxoline. Pathol. Biol. 1987; 35 (5, pt 2): 873-878.
- Jick S. S., Jick H., Walker A. M., Hunter J. R. Hospitalizations for pulmonary reactions following nitrofurantoin use. Chest 1989; 96 (3): 512-515.
- Westphal J. F., Vetter D., Brogard J. M. Hepatic side-effects of antibiotics. J. Antimicrob. Chemother. 1994; 33 (3): 387-401.
- Reeves D. L. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study. J. Antimicrob. Chemother. 1984; 13 (suppl. B): 99-105.
- Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int. J. Antimicrob. Agents 2001; 18 (3): 211-215.
- Holmes В., Brogden R. N., Richards D. M. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985; 30 (6): 482-513.
Supplementary files
